Surgery Websites
Transplant Surgery »  Meet the Team »  Hepatology »  Francis Y.K. Yao, M.D.
Francis Y.K. Yao, M.D.

Francis Y.K. Yao, M.D.

Professor of Clinical Medicine and Surgery,
Departments of Medicine and Surgery
Medical Director, Liver Transplant Service
Director for Community Liaison, Liver Transplant Service

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357
San Francisco, CA 94143-0358
Phone: (415) 514-0332
Fax: 415-476-0659
Francis.yao@ucsf.edu
Open Popup

1979-1980 University of San Francisco, Chemistry Major

1980-1983 University of California, Berkeley B.S. Chemistry with High Honors

1983-1987 Albert Einstein College of Medicine. M.D. Medicine

  • 1987-1988 Stanford University Hospital, Intern, Internal Medicine
  • 1988-1990 Stanford University Hospital, Resident, Internal Medicine
  • 1990-1993 Stanford University Hospital, Fellow, Gastroenterology
  • 1995 American Board of Internal Medicine - ABIM 147033 (Re-certification 2008)
  • 1997 American Board of Gastroenterology - ABIM 147033
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Liver Transplant Program
  • UCSF Liver Center
  • Hepatitis in Asians
  • Liver Injury and Repair
  • Liver transplantation outcomes including expanded criteria liver transplants
  • Loco-regional therapy for hepatocellular carcinoma

Dr. Francis Yao is a gastroenterologist and medical director of the Liver Transplant Program at UCSF Medical Center. Dr. Yao is a professor of medicine in the UCSF School of Medicine. He also is director of UCSF's Liver Transplant Outreach and Community Liaison Program. In his research, he is interested in liver cancer treatment, particularly related to liver transplants, and has contributed to important publications in this area. His other research interests include hepatitis B infection and outcomes for liver transplantation.

MOST RECENT PUBLICATIONS FROM A TOTAL OF 121
Data provided by UCSF Profiles, powered by CTSI
  1. Mehta N, Yao FY. Liver Transplantation After Downstaging of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Using Yttrium-90 Radioembolization: Pipe Dream or Reality? Liver Transpl. 2021 Sep 16. View in PubMed
  2. Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology. 2021 Jul 28. View in PubMed
  3. Lokken RP, Kerlan RK, Chung YC, Chen YF, Mehta NJ, Yao FY, Fidelman N. Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol. 2021 05; 216(5):1283-1290. View in PubMed
  4. Harding-Theobald E, Yao FYK, Mehta N. Neutrophil-to-Lymphocyte Ratio Predicts High-Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl. 2021 06; 27(6):818-829. View in PubMed
  5. Kotwani P, Chan W, Yao F, Mehta N. DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study. Clin Gastroenterol Hepatol. 2021 Jan 29. View in PubMed
  6. View All Publications

 

Site Directory
    X